To help you understand what is going on in the drug and pharmaceutical industry and what we expect to happen in the future, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
At the very least, 2024 will be better than 2023 for the pharma industry. Swiss pharma giant Roche will score the most sales ($55 billion) of any drugmaker next year on the strength of its biologics portfolio, including Ocrevus, a treatment for MS, as well as anti-cancer agent Tecentriq and hemophilia drug Hemlibra.
Johnson & Johnson (JNJ), Merck, AbbVie (ABBV) and Pfizer will exceed $50 billion in sales, too. But Pfizer, the world’s top-selling drugmaker last year, will fall to fifth place due to declining sales for its pandemic-related treatments.
Another notable change: Novo Nordisk will enter the top 10, supplanting GSK (formerly GlaxoSmithKline). Novo Nordisk will boast the two biggest generators of new drug sales, which are both weight loss-related: Wegovy ($4 billion in new sales) and Ozempic ($3 billion).
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Combined, total sales of the drugs, which both employ the same active ingredient, Semaglutide, will rival those of Keytruda, the world’s best-selling pharmaceutical. Keytruda, a cancer immunotherapy drug manufactured and marketed by Merck, will generate over $25 billion this year.
Beyond Keytruda, Wegovy and Ozempic, other top sellers include Sanofi and Regeneron’s Dupixent, which is used to treat allergic diseases like eczema, asthma and nasal polyps, Eliquis, the Pfizer and Bristol Myers Squibb drug used to prevent blood clots, and Gilead’s Biktarvy, a fixed-dose combination medication for the treatment of HIV and AIDS.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
-
Apple Readies for AI Upgrade with New iPhonesThe Kiplinger Letter The tech giant has stumbled when it comes to artificial intelligence, but a new batch of iPhones will help it make headway.
-
Japan Enters a New Era of Risk and ReformThe Kiplinger Letter Japan has entered a pivotal moment in its economic history, undertaking ambitious policy and structural reforms to escape from decades of stagnation.
-
How Consumers Are Tinkering with Cutting-Edge AIThe Kiplinger Letter Companies launching artificial intelligence tools are jostling for consumer attention. Some products are already building a deep connection with users.
-
After Years of Stagnant Growth, Hope Emerges for EU EconomyThe Kiplinger Letter Can a German fiscal push outweigh French political peril?
-
Small Businesses Are Racing to Use AIThe Kiplinger Letter Spurred on by competitive pressures, small businesses are racing to adopt AI. A recent snapshot shows the technology’s day-to-day uses.
-
How AI Puts Company Data at RiskThe Kiplinger Letter Cybersecurity professionals are racing to ward off AI threats while also using AI tools to shore up defenses.
-
AI Start-ups Are Rolling in CashThe Kiplinger Letter Investors are plowing record sums of money into artificial intelligence start-ups. Even as sales grow swiftly, losses are piling up for AI firms.
-
What is AI Worth to the Economy?The Letter Spending on AI is already boosting GDP, but will the massive outlays being poured into the technology deliver faster economic growth in the long run?
